Does quetiapine increase serum cortisol, and how should it be managed in patients with cortisol‑sensitive conditions?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 6, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Quetiapine and Cortisol

Quetiapine decreases, not increases, serum cortisol levels through its effects on the hypothalamic-pituitary-adrenal (HPA) axis, and this reduction should be monitored in patients with cortisol-sensitive conditions to avoid potential hypocortisolism.

Effect on Cortisol Levels

Quetiapine has a well-documented cortisol-lowering effect. In a randomized, double-blind, placebo-controlled study of healthy volunteers, quetiapine (50 mg) significantly reduced both ACTH and cortisol secretion compared to placebo 1. This effect was observed within hours of administration, with cortisol decreasing from 150 minutes post-dose through the end of the observation period 2. The mechanism likely involves quetiapine's antagonism of serotonergic receptors (particularly 5-HT2), though blockade of adrenergic or histaminergic receptors may also contribute 1.

Clinical Significance

The cortisol reduction is clinically meaningful:

  • A case report documented reversible hypocortisolism in a patient using quetiapine, with low early morning cortisol levels and abnormal tetracosactide testing that normalized after quetiapine discontinuation 3
  • The HPA-axis down-regulation may contribute to quetiapine's therapeutic effects on depressive symptoms and cognitive functioning 1
  • This effect occurs even at low doses (25-75 mg/day), where cortisol reduction may be a therapeutic mechanism 4

Management in Cortisol-Sensitive Conditions

Patients to Monitor Closely

Avoid or use extreme caution in patients with:

  • Pre-existing adrenal insufficiency (primary or secondary)
  • Glucocorticoid-induced adrenal insufficiency recovering from exogenous steroid use
  • History of hypopituitarism
  • Concurrent use of other medications that suppress the HPA axis

Monitoring Protocol

For patients requiring quetiapine who have cortisol-sensitive conditions:

  1. Baseline Assessment

    • Measure morning cortisol (ideally between 0800-0900 hours) before initiating quetiapine
    • Consider baseline ACTH if secondary adrenal insufficiency is suspected
    • Document symptoms of adrenal insufficiency (fatigue, malaise, weakness, hypotension)
  2. During Treatment

    • Recheck morning cortisol at 2-4 weeks after initiation or dose escalation
    • Monitor for symptoms of hypocortisolism: persistent fatigue, malaise, orthostatic hypotension, nausea
    • Use cortisol values as a continuum rather than arbitrary cutoffs 5
    • Morning cortisol <150 nmol/L (5 μg/dL) indicates likely persistent adrenal insufficiency 5
    • Morning cortisol >300 nmol/L (10 μg/dL) suggests adequate HPA function 5
  3. If Hypocortisolism Develops

    • Temporarily treat with physiologic hydrocortisone replacement
    • Taper quetiapine if clinically feasible 3
    • Reassess cortisol production after quetiapine discontinuation
    • If quetiapine must be continued, maintain lowest effective dose with glucocorticoid replacement

Important Caveats

Assay considerations: Cortisol measurement varies by assay method. Immunoassays can differ by up to 170 nmol/L in cutoff values compared to mass spectrometry 5. Familiarize yourself with your laboratory's specific reference ranges and methodology.

Confounding factors that affect cortisol interpretation 5:

  • Disrupted circadian rhythm (night shift work, severe insomnia) can falsely lower morning cortisol
  • Oral estrogens elevate cortisol-binding globulin, increasing total cortisol without affecting free cortisol 6
  • Hypoalbuminemic states (cirrhosis, nephrotic syndrome) decrease measured cortisol
  • Timing: ensure samples are drawn at least 24 hours after last glucocorticoid dose (excluding dexamethasone)

Contraindication Context

While the FDA label for quetiapine does not specifically list adrenal insufficiency as a contraindication 7, the documented cortisol-lowering effect 1, 2 and case report of quetiapine-induced hypocortisolism 3 warrant extreme caution in patients with compromised HPA axis function.

The key clinical principle: Quetiapine's cortisol-lowering effect is opposite to what the question implies—it does not increase cortisol but rather suppresses it, creating risk in patients who cannot tolerate further HPA axis suppression.

References

Research

Neuroendocrine effects of quetiapine in healthy volunteers.

The international journal of neuropsychopharmacology, 2005

Research

Atypical hypocortisolism.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2013

Related Questions

Do bupropion (Wellbutrin XL), lisdexamfetamine (Vyvanse), or quetiapine (Seroquel) affect cortisol levels?
What is the recommended approach for using atypical antipsychotics, such as quetiapine (Seroquel), for anxiety in patients with bipolar disorder?
What is the best treatment strategy for a 27‑year‑old female with Bipolar I disorder currently in a depressive episode, comorbid post‑traumatic stress disorder, generalized anxiety disorder with severe panic attacks, secondary insomnia, chronic pain, and obesity, who has failed multiple medication trials including citalopram 20 mg, fluoxetine 20 mg, olanzapine 10 mg, propranolol 20 mg three times daily, quetiapine extended‑release 50 mg at bedtime, and sertraline 50 mg?
Can the NuvaRing (etonogestrel/ethinyl estradiol vaginal contraceptive ring) cause an elevation in hematocrit or cortisol levels?
For a 66-year-old male with major depressive disorder and generalized anxiety disorder living in an assisted‑living facility, currently taking clonazepam 1 mg three times daily, desvenlafaxine extended‑release 50 mg daily, and quetiapine (Seroquel) 100 mg four times daily plus 50 mg three times daily, and with a PHQ‑9 score of 9, what medication adjustments are recommended if he refuses to stop clonazepam?
Can lisinopril cause thinning of the skin and increased bleeding?
Does daily testosterone injection reduce aromatization and estradiol (E2) levels?
What burden of premature atrial contractions (PACs) is sufficient to precipitate atrial fibrillation?
Is the rash associated with scabies warm to the touch?
How often does the Rapid Plasma Reagin (RPR) titer fluctuate?
Is West Nile virus contagious via person-to-person transmission?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.